Court Victory for Pfizer

A judge denies a bid by Novo Nordisk to halt sales of the inhaled insulin Exubera.
Publish date:


(PFE) - Get Report

said a federal judge has denied a bid by Denmark's

Novo Nordisk

(NVO) - Get Report

to halt sales of the inhaled insulin Exubera.

Novo Nordisk, which is working on its own inhaled insulin,

sued Pfizer in August for patent infringement. On Thursday, a judge in New York rejected Novo Nordisk's request for a preliminary injunction until the patent suit is resolved. A Pfizer spokesman said a trial date hasn't been set.

Pfizer developed Exubera with

Nektar Therapeutics

(NKTR) - Get Report


Approved by the FDA in January, Exubera, a dry powder form of insulin, has been

reaching markets slowly since July.

Pfizer says a full-scale launch of the drug to primary care physicians will begin in January.

Novo Nordisk is working on AERx, an inhaled form of liquid insulin, using technology developed by



. Analysts say it will still take about four years for this product to be available.